A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004

NCT ID: NCT06857695

Last Updated: 2025-05-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-06
• Study Completion Date: 2025-05-05

Brief Summary

This study in healthy volunteers aims to answer these questions:

• Does the test medicine cause any important side effects?
• What are the blood levels of the test medicine and how quickly does the body get rid of it?
• How much of the test medicine taken by mouth gets into the bloodstream?
• How does the body break down and get rid of the test medicine?

This study will take place at one site in Nottingham, United Kingdom, and plans to enrol 8 healthy men aged 30-65 years, who will be involved in both parts of the study.

Detailed Description

In this 2-part study, healthy volunteers will be given three doses of test medicine to find out how the body breaks down and gets rid of the test medicine. Two doses will be 'radiolabelled' - they will contain a small amount of radioactivity (Carbon-14) so that it can be tracked in the body. The amount of radiactivity is less than 6 days of the average radiation exposure received in the UK each year, and slightly less than the radiation dose that would result from a single head x-ray or two leg x-rays.

This study in healthy volunteers aims to answer these questions:

• Does the test medicine cause any important side effects?
• What are the blood levels of the test medicine and how quickly does the body get rid of it?
• How much of the test medicine taken by mouth gets into the bloodstream?
• How does the body break down and get rid of the test medicine?

This study will take place at one site in Nottingham, United Kingdom.

It plans to enrol 8 healthy men aged 30-65 years, who will be involved in both parts of the study.

In Part 1, volunteers will receive a single dose of the test medicine by mouth and, on the same day, a very tiny dose of radiolabelled study medicine by injection into a vein. After a minimum of 7 days, in Part 2, volunteers will receive a dose of test medicine containing a very tiny amount of radio label, by mouth. They'll stay in the clinic for up to 6 nights in Part 1 and 8 nights in Part 2 and take up to 7 weeks to finish the study.

We'll collect blood and urine samples to do safety tests. Over a period of at least 15 days, we'll take many blood samples. In Part 2 volunteers will collect all their urine and faeces so that we can measure the amount of test medicine and its breakdown products.

Conditions

Healthy Participants

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AZD5004

A single dose of AZD5004 film-coated tablet and a single dose of [14C]AZD5004 Solution for Infusion (Part 1)

A single dose of [14C]AZD5004 Oral Solution (Part 2)

Group Type: EXPERIMENTAL

AZD5004 film-coated tablet

Intervention Type: DRUG

oral, fasted

[14C]AZD5004 Solution for Infusion

Intervention Type: DRUG

intravenous, fasted

[14C]AZD5004 Oral Solution

Intervention Type: DRUG

oral, fasted

Interventions

AZD5004 film-coated tablet

oral, fasted

Intervention Type: DRUG

[14C]AZD5004 Solution for Infusion

intravenous, fasted

Intervention Type: DRUG

[14C]AZD5004 Oral Solution

oral, fasted

Intervention Type: DRUG

Other Intervention Names

AZD5004; [14C]AZD5004; [14C]AZD5004

Eligibility Criteria

Inclusion Criteria

• Healthy males aged 30 to 65 years inclusive
• BMI in the range 18.0 - 35.0 kg/m2 and body weight ≥63 kg
• Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)

Exclusion Criteria

• History of any clinically significant disease or disorder
• History or presence of clinically significant gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
• History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity
• Excessive intake of caffeine containing drinks or food
• History/family history of medullary thyroid carcinoma or multiple endocrine neoplasia
• Uncontrolled thyroid disease
• History of acute pancreatitis or gallstones
• Serum triglyceride concentrations > 1000 mg/dL (11 mmol/L)
• Any history of significant inflammatory bowel disease, gastroparesis, or other severe disease or prior surgery affecting the upper GI tract
• Participants who do not have suitable veins for multiple venepunctures/cannulation
• Clinically significant abnormal clinical chemistry, haematology or urinalysis
• Significant hepatic disease
• Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting ECG and any clinically important abnormalities in the 12-lead ECG
• Abnormal renal function
• Radiation exposure exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years, occupationally exposed worker, or have been administered IMP in a [14C] ADME study in the last 12 months.
• Use of any prescribed or non-prescribed medication
• Current smokers or known or suspected history of alcohol or drug abuse.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Quotient Sciences

INDUSTRY

Sponsor Role: collaborator

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sharan Sidhu, MBChB, BAO, MRCS, MFPM

Role: PRINCIPAL_INVESTIGATOR

Quotient Sciences

Locations

Research Site

Ruddington, , United Kingdom

Countries

United Kingdom

Other Identifiers

D7260C00010

Identifier Type: -

Identifier Source: org_study_id